Open the map

NateraNTRA

Diagnostics · NASDAQ · USA

$390.79
Down 1.2% todayClose

Up 72.7% this year and +49.2% since June 26, ahead of the life science sector at +10.7%. Natera supplies 1 mapped company and buys from 1.

This year
+72.7%
1 year
+134.7%
P/E
n/a
P/S
20.5
P/B
30.5

Price vs the life science sector

since Jun 26NTRALife science sector, equal weight
Natera (NTRA) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. NTRA: +49.2% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+20%+40%+60%Jun 26AugSepOct 8NTRA +49.2%Sector +10.7% Natera (NTRA) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. NTRA: +49.2% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+20%+40%+60%Jun 26AugSepOct 8NTRA+49.2%Sector+10.7%

Supply chain

1 supplier · 1 customer
SUPPLIERS →→ CUSTOMERSIllumina (ILMN)ILMNIllumina−1.2%UnitedHealth (UNH)UNHUnitedHealth−1.3%NTRANatera Open the full chain →

About Natera

Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.

Theme exposure

Genetic diagnosticsOncology testingPrenatal screening

Products

  • Prenatal screening (Panorama)
  • Oncology testing (Signatera)
  • Transplant diagnostics

Competitors

  • Guardant Health
  • Exact Sciences
  • Myriad Genetics

Risks

  • Reimbursement & coverage
  • Patent disputes

Same segment: Diagnostics

Tests, imaging and assays that support clinical decision-making. Segment 6 of 8 in the Medicine, pharma & life science value chain.

Compare NTRA

Side by side with the largest companies in the same segment.

See where Natera sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →